Drug Approval | August 06, 2023
Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
The product is being launched in August 2023
The product is being launched in August 2023
The product is bioequivalent and therapeutically equivalent to the reference listed drug by Fresenius Kabi USA, LLC.
According to IQVIA sales data for the 12-month period ending January 2025, the Vancomycin Hydrochloride for Injection USP, 750 mg/vial, 1.25 g/vial and 1.5 g/vial (Single-dose vial) market achieved annual sales of approximately $39.3 mn
Subscribe To Our Newsletter & Stay Updated
